Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Sep 8, 2021
Deals
Like a ROCK: Sanofi takes out Kadmon for $1.9B, gains transplant drug
Takeout of the Waksal-led biotech comes on the heels of the approval of the company’s ROCK2 inhibitor for GvHD
BioCentury | Mar 28, 2016
Strategy
Canbridge can-can
Why Aveo's AV-203 is leading Canbridge to venture outside Asia
BioCentury | Feb 17, 2014
Emerging Company Profile
Canbridge: A bridge to China
Genzyme alumni at Canbridge in-licensing Western programs to develop in China
BioCentury | Feb 21, 2011
Strategy
BioMarin wants control
BioMarin, sanofi in talks to determine future of rights to Aldurazyme
BioCentury | Oct 25, 2010
Finance
Argument for $89
Genzyme itemizes why it's worth $89 a share, not $69 bid by sanofi-aventis
BioCentury | Jun 21, 2010
Strategy
Playing Brazil
Beyond generics: Strategies for growing innovator drug sales in Brazil
Items per page:
1 - 10 of 120